Alopecia areatahttps://en.wikipedia.org/wiki/Alopecia_areata
Alopecia areata bụ ọnọdụ mpaghara ebe ntutu na-apụ n'ahụ. Ọtụtụ mgbe, ọ na-ebute ntụpọ nkwọcha ole na ole n'isi, nke ọ bụla hà ka otu mkpụrụ ego. Enwere ike ịkpata ọrịa ahụ site na nrụgide uche.

Ekwenyere na alopecia areata bụ ọrịa autoimmune metụtara usoro ahụ ji alụso ọrịa ọgụ nke ntutu isi. Usoro dị n'okpuru na-agụnye ọdịda nke ahụ ahụ na-amataghị mkpụrụ ndụ nke ya, na-enwe mbibi na-esote usoro mgbochi nke mgbochi nke ntutu isi.

Ọgwụgwọ ― OTC Ọgwụ
Ụfọdụ ndị nwere alopecia areata dị nro na-agbake n'ime otu afọ na-enweghị ọgwụgwọ. Agbanyeghị, ọtụtụ ndị mmadụ na-enweta nlọghachi na saịtị enweghị usoro na isi isi.
#Hydrocortisone cream

Ọgwụgwọ
Intralesional steroid injections bụ ọgwụgwọ kacha dị irè. Enwere ike ịnwale ọgwụ mgbochi ọrịa ma ọ bụrụ na emetụta akụkụ buru ibu nke isi isi.
#Triamcinolone intralesional injection
#DPCP immunotherapy
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
  • A na-ahụ Alopecia areata n'azụ isi isi. N'ọnọdụ ndị a na-ahụkarị, ọ na-apụta na mberede na elu zuru oke na nha nke 2-3 cm.
  • Mfu ntutu okirikiri okirikiri
References Alopecia areata 28300084 
NIH
Alopecia areata bụ ọnọdụ ebe usoro ahụ ji alụso ọrịa ọgụ na-awakpo ntutu isi gị, na-ebute ntutu isi nwa oge na-enweghị ọnya. Ọ nwere ike igosipụta dị ka ntụpọ nke ntutu isi ma ọ bụ na-emetụta isi ma ọ bụ ahụ gị dum, na-emetụta ihe dịka 2% nke ndị mmadụ n'oge ụfọdụ na ndụ ha. Isi ihe kpatara ya yiri ka ọ bụ mmebi nke nchebe okike gburugburu ntutu isi.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
 Alopecia Areata: An Updated Review for 2023 37340563 
NIH
Alopecia areata bụ ọnọdụ ebe usoro ahụ ji alụso ọrịa ọgụ na-awakpo ntutu isi, na-ebute ntutu isi n'isi na akụkụ ahụ ndị ọzọ nwere ntutu. Ọ na-emetụta ihe dịka 2% nke ndị mmadụ n'ụwa nile. Ọ bụ ezie na ọ nwere ike ime n'afọ ọ bụla, ọ na-adịkarị na ụmụaka karịa ndị okenye (1. 92% vs. 1. 47%) . Ụmụ nwanyị, karịsịa ndị gafere 50, na-enwekarị ahụmahụ karịa ụmụ nwoke. Ịgbanye corticosteroids ozugbo n'ime ebe ihe metụtara egosila nsonaazụ dị mma karịa itinye ha n'elu.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.